Business Wire

GCEX

10.5.2023 08:05:26 CEST | Business Wire | Press release

Share
GCEX Granted License by Danish FSA to Operate as an Investment Firm

GCEX, a leading digital prime brokerage, has been granted permission from the Danish Financial Supervisory Authority (FSA) to operate as an investment firm.

The FSA license is a significant milestone for GCEX, enabling the rapidly growing firm to offer rolling Spot FX and CFDs to institutional clients in the EU.

Michael Aagaard, Managing Director, GCEX, Denmark said, “This is a major step forward for our business and we believe it will be a significant catalyst for growth in Europe. Brokers, fund managers, hedge funds and professional traders based in the EU will now have the peace of mind and reassurance of knowing that they are transacting with a credible firm which is regulated in their own jurisdiction.”

Lars Holst, CEO, GCEX added, “It is fantastic news that we now have access to the EU market as an investment firm regulated by the Danish FSA. Obtaining this FSA license involved an extremely stringent process in which we had to demonstrate our experience in financial services, the knowledge of our team, good governance and our strong focus on investor protection. It now opens the door for us to market to EU clients, presenting us with a major opportunity for further growth.”

“From the outset, we have been advocates of operating within strong regulatory environments. Our broader regulatory coverage reflects our ethos of providing a professional, reliable, trusted and robust service in order to be at the forefront of the industry.”

Headquartered in London with multiple offices around the globe including in Copenhagen, GCEX Group enables brokers, fund managers, hedge funds and professional traders to access deep liquidity in FX and CFDs. The firm also offers clients access to XplorDigital, a range of trading solutions.

True Global Ventures are investors in GCEX.

For further information, please visit www.gc.exchange or LinkedIn

Ends –

About GCEX

Founded in 2018, GCEX is a pioneering regulated digital prime brokerage with a best-of-breed digital asset and FX platform for institutional and professional clients. GCEX has partnerships with Tier 1 trusted Liquidity Providers, leading counterparties and regulated digital custody asset institutions. GCEX offers a wide range of products and technology solutions including White Labels.

GCEX is a trading name of GC Exchange Limited, GC Exchange Fondsmæglerselskab A/S, GC Exchange A/S and GC Exchange FZE.

GC Exchange Limited, a company incorporated in England and Wales (No11382809) with registered address at 75 King William Street, London, EC4N 7BE provides FX and CFDs products. GC Exchange Limited is authorised and regulated by the Financial Conduct Authority (FRN 828730).

Digital asset services are provided by GC Exchange A/S, a company incorporated in Denmark (CVR 43088777) with address at Amager Strandvej 390, 2770, Kastrup. GC Exchange A/S is authorised by the Danish Financial Supervisory Authority as a Currency Exchange (FTID 45020) and registered as a Virtual Asset Service Provider (FTID 17524) under the AML regulation.

GC Exchange Fondsmæglerselskab A/S, a company incorporated in Denmark (CVR 43345052) with address at Amager Strandvej 390, 2770, Kastrup. GC Exchange Fondsmæglerselskab A/S is authorised by the Danish Financial Supervisory Authority as an Investment Firm to offer FX and CFDs products.

GC Exchange FZE is incorporated as a Limited Liability Free Zone Establishment under the Dubai World Trade Center Authority with registration number 1896. GC Exchange FZE has been granted a Virtual Asset Service Provider License for the MVP phase by the Dubai Virtual Assets Regulatory Authority.

For further information, please visit www.gc.exchange or LinkedIn

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005921/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye